Analysis of KRYSTEXXA Phase III Data Demonstrates Improved Health-Related Quality of Life and Physical Function in Refractory

Savient Pharmaceuticals, Inc. SVNT today announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA^® (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function. The article confirms that chronic gout, especially refractory chronic gout, is associated with decline in HRQOL and physical functioning compared to patients without chronic gout.  The results were published in the print edition of the July 2012 issue of The Journal of Rheumatology.